Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases
Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.
Multiple Sclerosis
Program
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Remyelination program
Stage: Preclinical
Expanded Access Policy
Learn about our expanded access policy.
Our Program for Multiple Sclerosis
Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosis
Learn More